Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Ellagic Acid: Mechanism and Evidence Boundaries

    2026-10-15

    Ellagic acid is a polyphenolic compound that APExBIO lists under SKU A2306. The product page gives the CAS number 476-66-4, molecular formula C14H6O8, molecular weight 302.19, and the systematic chemical name 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione. The shorter phrase 2,3,7,8-tetrahydroxychromeno chromene dione is a useful search descriptor, but the catalogued systematic name is the more specific identity statement. These details document how the supplier identifies the material; they are not, by themselves, independent analytical authentication or evidence of biological performance. The supplier’s product description is available through the Ellagic acid catalog page.

    Documented identity and scientific context

    The APExBIO description positions Ellagic acid as a research compound relevant to casein kinase 2, cancer biology research, oxidative stress assay contexts, and apoptosis research. It also uses the descriptors antioxidant, antitumor, and anticarcinogenic. Those descriptors should be treated as product-level claims rather than as reported outcomes from a matched study. The available information does not identify a cellular model, animal model, patient population, comparator treatment, or measured endpoint supporting those broader biological labels.

    This distinction matters because a chemical identity and a proposed molecular target answer different questions. Identity information addresses what compound the supplier says is being offered. Mechanistic evidence must establish how the named compound affects a target under a defined measurement context. Translational evidence must then show whether that molecular effect produces a reproducible phenotype in a relevant biological system.

    Documented mechanism and measurement principle

    The product description characterizes Ellagic acid as a selective ATP-competitive CK2 inhibitor and reports an IC50 of 40 nM for CK2. In conceptual terms, ATP competition indicates that the stated interaction is associated with the kinase’s ATP-binding site. An IC50 is the concentration associated with a 50% reduction in the measured activity under the conditions of a particular assay; it is not automatically a binding constant, a cellular concentration, or a measure of clinical potency.

    The reported 40 nM value is therefore best read as a product-description claim about a biochemical measurement. Its meaning depends on features that are not provided here, including the assay format, ATP concentration, substrate, enzyme preparation, replicate structure, curve-fitting model, and uncertainty. Without those details, the numerical value cannot be independently assessed or directly compared with IC50 values generated in different assay systems.

    The page also states that Ellagic acid is substantially less potent against Lyn, PKA, Syk, and FGR than against CK2. This supports, at most, a relative preference within the listed comparison panel. It does not establish selectivity across the kinome, nor does it show that CK2 is the sole biologically relevant target in cells. A biochemical result can support a target hypothesis; it does not by itself establish target engagement in a complex cellular environment.

    Interpreting downstream biological claims

    The causal sequence is important: an interaction with CK2 could alter phosphorylation of downstream substrates, which could in turn influence signaling, stress responses, cell-cycle behavior, or apoptotic markers. Measurements such as reduced viability, increased apoptotic markers, or altered reactive oxygen species would be downstream observations. They would not, without additional target-specific evidence, prove that CK2 inhibition caused the phenotype.

    This distinction is especially relevant to oxidative stress assay and apoptosis research. Antioxidant or pro-apoptotic readouts can arise from multiple mechanisms, including chemical reactivity, changes in cellular redox balance, general toxicity, altered metabolism, or effects on targets other than CK2. The product description does not provide outcome data that separate these explanations. Accordingly, it supports a mechanistic research question about CK2 more clearly than it supports a general claim that Ellagic acid produces a particular cancer or stress phenotype.

    Product properties and measurement scope

    APExBIO describes Ellagic acid as poorly soluble in water and ethanol and identifies solvent and stability considerations for preparing or maintaining material. These are relevant measurement-context properties, not biological outcomes. Limited solubility or changes in solution stability can affect the relationship between a nominal concentration and the freely available compound, potentially complicating interpretation of apparent biochemical or cellular potency. The product information does not quantify the effect of those variables on the reported CK2 value or on any cellular endpoint.

    The same boundary applies to the page’s references to cancer therapeutics. A catalog statement that a compound is used in biochemical or cellular assays does not demonstrate efficacy in a tumor model, therapeutic index, pharmacokinetics, or clinical treatment. No clinical recommendation follows from the information available here.

    Claim, reported evidence, and interpretation

    Claim Reported evidence Proportionate interpretation
    Compound identity CAS 476-66-4, formula C14H6O8, molecular weight 302.19, and a systematic chemical name are listed by APExBIO. This documents the supplier’s identity description, not independent confirmation of material quality or biological activity.
    CK2 inhibition The product page reports ATP-competitive inhibition of CK2 with an IC50 of 40 nM. This is a reported biochemical potency value. No sample size, uncertainty, assay format, or independent replication is supplied.
    Relative selectivity The page states lower potency against Lyn, PKA, Syk, and FGR. This supports only a limited comparison among named kinases; it does not establish broad target selectivity.
    Antioxidant, antitumor, and anticarcinogenic activity These are descriptive claims in the product information, without model-specific outcomes or statistics. They should not be treated as validated cellular, animal, or clinical findings for this material.

    Evidence availability and applicability boundaries

    No identity-matched research paper is available for this assessment. The evidence base therefore consists of the product description rather than a primary study with a documented design, matched material provenance, prespecified comparators, quantitative uncertainty, and biological outcome measures. The strongest numerical statement is the reported 40 nM CK2 IC50; the supplied information does not include a confidence interval, replicate count, concentration–response data, or independent confirmation.

    A related contextual article, Ellagic Acid: Evidence and Applicability Boundaries, is relevant only for its stated caution that a reported CK2 activity profile should not be equated with validated senolytic activity. It is not an identity-matched primary study and therefore cannot add evidence for Ellagic acid’s efficacy, selectivity, or cellular mechanism.

    • Biochemical scope: The available information supports a narrowly framed claim about a reported CK2 inhibition measurement and a qualitative comparison with four named kinases.
    • Cellular scope: The product description does not establish intracellular CK2 engagement, pathway selectivity, or a causal relationship between CK2 inhibition and apoptosis or oxidative-stress readouts.
    • Cross-domain scope: Antioxidant, antitumor, anticarcinogenic, and senolytic interpretations require evidence from their respective models and cannot be inferred from the catalogued IC50 alone.
    • Translational scope: Nothing in the available information establishes pharmacology, safety, therapeutic benefit, or clinical applicability.

    Factual synthesis

    Ellagic acid is documented by APExBIO as a defined polyphenolic compound with a reported selective, ATP-competitive CK2 inhibition profile and a CK2 IC50 of 40 nM. That result is meaningful as a stated biochemical measurement, but its interpretation is constrained by the absence of assay details, uncertainty estimates, an expanded selectivity panel, and identity-matched biological studies. The product page can therefore support a focused discussion of CK2-related measurement and hypothesis formation, while the broader claims concerning oxidative stress, apoptosis, cancer biology, antitumor activity, or senolytic effects remain unestablished within the evidence provided.